PD-1 blockade plus capecitabine as curative-intent treatment for tumor mutational burden-high multi-metastatic pancreatic ductal adenocarcinoma: A case report

Abstract excerpt

<title>Abstract</title> <p> The rising incidence and persistently dismal 5-year overall survival of pancreatic ductal adenocarcinoma (PDAC) highlight the need for effective new systemic therapies. Cancer immunotherapy has increasingly garnered attention. Various methods, such as cell therapy, immune-checkpoint blockers (ICBs), and cancer vaccines, alone or in combination, have achieved satisfactory results in ca...

Topics

Open a Topic to create a Post that cites this publication.

• Antibodies, Monoclonal, Humanized
• Carcinoma, Pancreatic Ductal
• DNA
• Immune Checkpoint Inhibitors
• Molecular Targeted Therapy
• Mutation
• Neoplasm Recurrence, Local
• Pancreatic Neoplasms

Identifiers and source

Literature Corpus work

58cbdc99-60dd-5e48-a666-61cbf9c5a23e

DOI

10.21203/rs.3.rs-7202690/v1